Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ...
-- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index -- -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral presentations delivered today during …